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Abstract
Background: Hodgkin lymphoma (HL) survivors have an increased risk of gastro-
intestinal (GI) cancer. This study aims to evaluate whether survival of patients who 
survived HL and developed GI cancer differs from survival of first primary GI can-
cer patients.
Methods: Overall and cause‐specific survival of GI cancer patients in a HL survivor 
cohort (GI‐HL, N = 104, including esophageal, gastric, small intestinal, and colorec-
tal cancer) was compared with survival of a first primary GI cancer patient cohort 
(GI‐1, N = 1025, generated by case matching based on tumor site, gender, age, and 
year of diagnosis). Cox proportional hazards regression was used for survival 
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1 |  INTRODUCTION
Hodgkin lymphoma (HL) survivors are at increased risk of 
developing second malignancies, which are a major cause 
for morbidity and mortality.1-4 Compared with the general 
population, the risk of developing gastrointestinal (GI) can-
cer is approximately 5‐fold higher in HL survivors.3-9 This 
risk remains elevated up to 40 years after HL and is strongly 
related to HL treatment.4 Both exposure to radiotherapy and 
alkylating agents, such as procarbazine or dacarbazine, have 
been associated with the development of GI cancers.3-7,9-11
A few studies suggest a difference in clinical and histo-
pathological characteristics of GI cancer in HL survivors 
compared with first primary GI cancer.12-14 To our knowl-
edge, only one previous study examined survival of GI can-
cer in HL survivors and reported a worse overall survival in 
subgroups of HL survivors compared with first primary GI 
cancer patients, that is, those diagnosed with TNM stage IIB‐
IV colon cancer and a small group (N = 8) of TNM stage I 
gastric cancer.13 No differences in disease‐specific survival 
were found.
The cause of the reported reduced overall survival of GI 
cancers in HL survivors remained unknown. Less favorable 
survival might be due to differences in (HL treatment‐in-
duced) carcinogenesis leading to differences in GI tumor 
characteristics, or to adaptation of GI cancer treatment due to 
the previous treatment for HL. Furthermore, increased risks 
of competing causes of death, such as other malignancies or 
cardiovascular disease, might play a role.15-17
In view of the reported worse overall survival of GI cancer 
in HL survivors and its unknown etiology, we designed this 
study to evaluate overall and cause‐specific survival of GI 
cancer in HL survivors.
2 |  PATIENTS AND METHODS
2.1 | Study design
This study compared overall and cause‐specific survival of 
esophageal, gastric, small intestinal, and colorectal cancer in 
a HL survivor cohort (GI‐HL) with survival of a population‐
based cohort of first primary GI cancer patients (GI‐1).
In a Dutch multicenter cohort of HL patients who sur-
vived at least 5 years after primary treatment (N = 2996), 
121 GI‐HL patients with carcinomas of the esophagus, stom-
ach, small intestine, or colorectum were identified. Data on 
HL patients, diagnosed in the period 1965‐2000 and between 
15 and 50 years of age at HL diagnosis, were collected as 
previously described.4,15 In short, data collection comprised 
detailed HL treatment data and information on second can-
cers, using medical records, by responses to questionnaires 
sent to general practitioners and linkage with the Netherlands 
Cancer Registry (NCR, from 1989 onwards).4 Finally, a total 
of 104 GI‐HL patients were used for analyses (Figure S1).
For each GI‐HL cancer, 10 matched controls of the Dutch 
general population with a GI‐1 cancer were identified, based 
on the following criteria: gender, no prior diagnosis of inva-
sive tumors, tumor location (esophagus, stomach, small in-
testine, or colorectum), year of diagnosis (closest proximity, 
maximum of 5 years difference), and age at diagnosis (clos-
est proximity, maximum of 3 years difference). For three GI‐
HL patients, it was not possible to obtain 10 matched GI‐1 
analyses. Multivariable analyses were adjusted for GI cancer stage, grade of differen-
tiation, surgery, radiotherapy, and chemotherapy.
Results: GI‐HL cancers were diagnosed at a median age of 54 years (interquartile 
range 45‐60). No differences in tumor stage or frequency of surgery were found. 
GI‐HL patients less often received radiotherapy (8% vs 23% in GI‐1 patients, 
P < 0.001) and chemotherapy (28% vs 41%, P = 0.01) for their GI tumor. Compared 
with GI‐1 patients, overall and disease‐specific survival of GI‐HL patients was worse 
(univariable hazard ratio (HR) 1.30, 95% confidence interval (CI) 1.03‐1.65, P = 0.03; 
and HR 1.29, 95% CI 1.00‐1.67, P = 0.049, respectively; multivariable HR 1.33, 95% 
CI 1.05‐1.68, P = 0.02; and HR 1.33, 95% CI 1.03‐1.72, P = 0.03, respectively).
Conclusions: Long‐term overall and disease‐specific survival of GI cancer in HL 
survivors is worse compared with first primary GI cancer patients. Differences in 
tumor stage, grade of differentiation, or treatment could not explain this worse 
survival.
K E Y W O R D S
gastrointestinal cancer, Hodgkin lymphoma, second malignancy, survival
192 |   RIGTER ET al.
patients because of the young age at diagnosis. Subsequently, 
data on GI cancer characteristics, treatment, and follow‐up 
were collected for both GI‐HL and GI‐1 patients.
From Statistics Netherlands (CBS), we obtained informa-
tion on the cause of death, which was categorized into GI 
cancer of interest or other causes, including unknown causes. 
As all data were processed and analyzed anonymously, this 
study was exempt from review by the Institutional Review 
Board.
2.2 | Statistical analyses
Patient and tumor characteristics of GI‐HL and GI‐1 patients 
were compared using chi‐square, Fishers’ exact, or Mann‐
Whitney U tests. Overall survival and cause‐specific survival 
were presented using the Kaplan‐Meier method. Cause‐spe-
cific survival was divided into disease‐specific survival, re-
lated to the GI cancer of interest, and survival related to other 
causes of death (using GI cancer‐related death as a censoring 
event).
In 12 out of 104 GI‐HL patients, the HL‐GI tumor was 
not the first diagnosis of a malignancy after HL. Since these 
other primary tumors or their treatment might affect survival, 
these 12 patients and their matched controls were excluded 
from further survival analyses (Table S1). Thus, 92/104 GI‐
HL tumors and their 911 matched controls were included in 
Cox proportional hazards regression models. We evaluated 
the effect of patient‐related and tumor‐related characteristics 
on the survival difference between GI‐HL and GI‐1 patients, 
that is on the HR associated with GI cancer in HL survivors 
(GI‐1 patients are included in the model as the reference 
population). We added each characteristic to the regression 
model and evaluated the influence of this characteristic on 
the survival difference between GI‐HL and GI‐1 patients, for 
example the hazard ratio. In case of a >10% change in the 
hazard ratio for death associated with the grouping variable 
(eg, GI‐HL vs GI‐1), this characteristic was considered to 
have a substantial influence on the survival difference be-
tween the groups. We also assessed disease‐specific mortal-
ity while treating other causes of death as a competing risk.
Analyses were performed using IBM SPSS Statistics 22 
and STATA version 14 (Armonk, New York).
3 |  RESULTS
3.1 | General description and comparison of 
GI‐HL and GI‐1 patients
GI‐HL cancers were diagnosed at a median age of 54 years 
(interquartile range (IQR) 45‐60). The majority occurred in 
males (67%). Patients were diagnosed with HL at a median 
age of 30 years (interquartile range (IQR) 22‐41, Table S1). 
Median year of HL diagnosis was 1981 (range 1966‐2000). 
In 53/104 (51%) patients, HL had been treated with both ra-
diotherapy and procarbazine‐containing chemotherapy and 
43/104 (41%) patients had been treated for a HL recurrence.
Due to the matching procedure, GI‐HL cancers were not 
different from GI‐1 cancers with respect to gender, age at di-
agnosis, and TNM stage (Table 1). GI‐HL patients were less 
frequently treated for their GI tumor with radiotherapy (8% 
vs 23% in GI‐1 patients, P < 0.001) or chemotherapy (29% vs 
41%, P = 0.01). Compared with GI‐1 tumors, GI‐HL tumors 
were treated more frequently with surgery alone and less fre-
quently with combined modality treatment that included ra-
diotherapy or chemotherapy (P = 0.005, Table 1).
3.2 | Gastrointestinal cancer: 
overall survival
Overall survival of 104 GI‐HL patients was worse than that 
of 1025 GI‐1 patients (hazard ratio (HR) 1.27, 95% confi-
dence interval (CI) 1.01‐1.58, P = 0.037). After exclusion 
of 12 GI‐HL patients with a third primary gastrointestinal 
tumor, overall survival in the remaining 92 GI‐HL patients 
was worse compared with 911 GI‐1 patients (HR 1.30, 95% 
CI 1.03‐1.65, P = 0.028, Table S1, Figure 1, Table 2).
In a multivariable model, adjusted for tumor character-
istics (TNM stage, grade of differentiation, tumor location), 
the difference between GI‐HL and GI‐1 patients remained 
present (HR 1.33, 95% CI 1.05‐1.68, P = 0.020). This dif-
ference also remained present after adjustment for treatment 
characteristics (surgery, radiotherapy, chemotherapy) and 
after adjustment for both tumor and treatment characteristics 
(HR 1.32, 95% CI 1.04‐1.68, P = 0.02; and HR 1.33, 95% CI 
1.05‐1.68, P = 0.02, respectively).
3.3 | Gastrointestinal cancer: cause‐
specific survival
Disease‐specific survival was worse in GI‐HL patients than 
in GI‐1 patients (HR 1.29, 95% CI 1.00‐1.67, P = 0.049, 
Table 3). Mortality from other causes appeared to be non-
significantly higher in GI‐HL patients compared with GI‐1 
patients (HR 1.44, 95% CI 0.81‐2.56, P = 0.22).
In a multivariable model adjusted for treatment charac-
teristics, disease‐specific survival remained worse in GI‐HL 
patients than in GI‐1 patients (HR 1.33, 95% CI 1.03‐1.72, 
P = 0.03). After adjustment for both tumor characteristics 
and treatment characteristics, this survival difference also re-
mained present (HR 1.33, 95% CI 1.03‐1.72, P = 0.03).
3.4 | Gastrointestinal cancer subsites
Within GI cancer subsites, locations of GI‐HL cancers dif-
fered significantly from locations of GI‐1 cancers (Figure 
2). Overall survival and disease‐specific survival were not 
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significantly different in GI‐HL esophageal cancer patients 
compared with GI‐1 patients (HR 1.20, 95% CI 0.79‐1.85, 
P = 0.41; and HR 1.17, 95% CI 0.75‐1.84, P = 0.49, respec-
tively, Figure 1, Table 2).
In GI‐HL gastric cancer patients, there was a trend toward 
worse overall and disease‐specific survival compared with 
GI‐1 patients (HR 1.33, 95% CI 0.91‐1.96, P = 0.15; and 
HR 1.43, 95% CI 0.95‐2.13, P = 0.08, respectively, Figure 
1, Tables 2 and 3). In several multivariable models, the over-
all and disease‐specific survival difference between GI‐HL 
gastric cancer patients and GI‐1 patients substantially in-
creased (>10% change in HR of the grouping variable GI‐HL 
vs GI‐1 patients; disease‐specific survival adjusted for sub-
site (antrum/pylorus vs other), HR 1.80, 95% CI 1.19‐2.74, 
P = 0.006; adjusted for stage, HR 1.66, 95% CI 1.11‐2.49, 
P = 0.01; adjusted for surgery, HR 2.00, 95% CI 1.33‐3.01, 
P = 0.001, Table S2). None of the evaluated characteristics 
decreased the survival difference, so none of these character-
istics could explain the observed difference in survival.
When comparing GI‐HL colorectal cancer patients with 
GI‐1 patients, overall survival and disease‐specific survival 
were not significantly different (HR 1.36, 95% CI 0.90‐2.06 
P = 0.15; and HR 1.27, 95% CI 0.77‐2.10, P = 0.35, res 
pectively). After adjustment for location either in colon or 
rectum, disease‐specific survival differences between GI‐
HL patients and GI‐1 patients became substantially smaller 
(HR 1.11, 95% CI 0.66‐1.86, P = 0.70, Table S2).
4 |  DISCUSSION
Our study is the first to demonstrate both a worse overall 
survival and disease‐specific survival of GI‐HL patients 
compared with survival of GI‐1 patients. Although some 
differences in GI tumor characteristics and treatment were 
present between GI‐HL patients and GI‐1 patients, none of 
these characteristics offered sufficient explanation for the 
survival differences. Mortality from other causes was not 
significantly higher in GI‐HL patients, but this could be due 
to a lack of statistical power. However, a higher rate of mor-
bidity may have influenced the efficacy of GI‐HL treatment. 
In addition, a different pathogenesis of therapy‐related GI 
cancer may affect the efficacy of GI‐HL treatment, resulting 
in worse survival.
A difference in carcinogenesis has been suggested only 
for therapy‐related colorectal cancer diagnosed in HL survi-
vors, as these tumors are more frequently microsatellite in-
stable due to somatic mutations in mismatch repair genes.14 
In therapy‐related esophageal cancer compared with sporadic 
cancer, no difference in frequency of microsatellite instability 
or loss of heterozygosity was found.12 To our knowledge, no 
data are available for therapy‐related gastric cancer and ther-
apy‐related small bowel cancer.G
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A second important finding of our study is that GI‐HL 
patients were treated differently compared with GI‐1 pa-
tients. GI‐HL patients were more frequently treated with 
surgery alone, and combined modality treatments were 
less frequently given. Probably due to prior HL treatment, 
radiotherapy and chemotherapy are given less frequently 
for GI‐HL patients, either as a result of dosage limitations 
or comorbidity.15,16 Additionally, the differences in treat-
ment may partially result from the distribution of GI cancer 
subsites in GI‐HL patients, as these were for example less 
frequently located in the rectum. Previous studies also re-
ported that therapy‐related GI cancers are more frequently 
located within irradiation fields.10,13,18 Surprisingly, the 
observed treatment differences did not explain the worse 
survival. Unfortunately, we did not have detailed data on 
GI cancer treatment regimens (eg, sequences of treatment, 
type of chemotherapy).
The only previous, comparable study performed used a 
similar study design but had somewhat different results.13 
They found a worse overall survival for HL survivors with 
TNM stage I gastric cancer (N = 8) and with TNM stage IIB‐
IV colorectal cancer (N = 70) compared with a significantly 
older population cohort with primary GI cancers. This study 
did not show a difference in overall survival for other stage 
subgroups or in disease‐specific survival. In addition, our 
methods of patient selection differed from Youn et al As GI‐
HL cancer is diagnosed at a relatively young age, we delib-
erately generated our population‐based comparison cohort 
with primary GI cancers by matching on age at diagnosis, and 
additionally on year of diagnosis and gender. We excluded 
GI‐HL patients with a second malignancy between HL and 
GI‐HL from survival analyses to increase comparability with 
the GI‐1 population. This selection method may have caused 
a decrease in mortality from other causes in the GI‐HL popu-
lation, resulting in a more comparable mortality from non‐GI 
cancer‐related causes for GI‐HL patients and GI‐1 patients.
The selection procedure of the population‐based con-
trols is one of the strengths of this study. Also, this is the 
first study with sufficient and long‐term follow‐up data to 
demonstrate a worse overall and disease‐specific survival in 
patients who survived HL and developed GI cancer and to 
provide data that excluded several possible etiologic factors.
The survival differences were, however, not large and the 
power was insufficient to confirm differences in survival 
F I G U R E  1  Overall survival 
of gastrointestinal cancer in Hodgkin 
lymphoma survivors (GI‐HL, blue) 
compared with first primary gastrointestinal 
cancer patients (GI‐1, green). *First primary 
gastrointestinal cancer patients; green line, 
number of cases at risk. †Gastrointestinal 
cancer in Hodgkin lymphoma survivors; 
blue line, number of cases at risk
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between GI‐HL and GI‐1 patients for GI cancer subsites, or 
for specific HL treatment exposure subgroups (as the major-
ity received combination treatments for HL, which limits sta-
tistical power). An additional limitation was the absence of 
information on other factors associated with GI cancer risk, 
such as family history and smoking status.
As HL survivors have an increased incidence of GI ma-
lignancies, and a slightly worse survival, treating physi-
cians should focus on GI cancer awareness and prevention. 
Personalized surveillance programs should be developed for 
this purpose. Our research group is currently performing a 
multicenter cohort study on a first surveillance colonos-
copy in HL survivors.19 (Dutch Trial Registry NTR4961) 
Additionally, further research is necessary to evaluate ther-
apy‐related GI carcinogenesis, as differences compared with 
sporadic carcinogenesis may have consequences for the clini-
cal approach, such as surveillance technique and interval.
In current clinical practice, decision‐making about curative 
HL treatment involves the balance of disease control and the 
risk of long‐term side effects. Due to the increased GI cancer 
risk associated with radiotherapy and procarbazine, and the as-
sociated increased mortality from GI cancer, the indication for 
the BEACOPP (including procarbazine) regimen should involve 
careful consideration and radiation fields should be limited.20
In conclusion, overall and disease‐specific survival of GI 
cancer patients is slightly worse in HL survivors compared 
with first primary GI cancer patients. Differences in tumor 
stage, grade of differentiation, treatment, or mortality from 
other causes could not explain the worse survival of GI can-
cer in HL survivors. As such, this may be explained by a 
worse treatment response due to HL‐related comorbidities or 
due to a different pathogenesis of therapy‐related GI cancer.
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